Your browser doesn't support javascript.
loading
Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance.
Muraoka, Daisuke; Harada, Naozumi; Shiku, Hiroshi; Akiyoshi, Kazunari.
Affiliation
  • Muraoka D; Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan. Electronic address: d.muraoka@aichi-cc.jp.
  • Harada N; United Immunity Co., Ltd., Tokyo, Japan.
  • Shiku H; Departments of Immuno-Gene Therapy and Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan.
  • Akiyoshi K; Department of Polymer Chemistry, Kyoto University Graduate School of Engineering, Kyoto, Japan. Electronic address: akiyoshi.kazunari.2e@kyoto-u.ac.jp.
J Control Release ; 347: 175-182, 2022 07.
Article in En | MEDLINE | ID: mdl-35526613
ABSTRACT
In therapeutic cancer vaccines, vaccine antigens must be efficiently delivered to the antigen-presenting cells (dendritic cells and macrophages) located in the lymphoid organs (lymph nodes and spleen) at the appropriate time to induce a potent antitumor immune response. Nanoparticle-based delivery systems in cancer immunotherapy are of great interest in recent year. We have developed a novel cancer vaccine that can use self-assembled polysaccharide nanogel of cholesteryl group-modified pullulan (CHP) as an antigen delivery system for clinical cancer immunotherapy for the first time. Additionally, we recently proposed a novel technology that uses CHP nanogels to regulate the function of tumor-associated macrophages, leading to an improvement in the tumor microenvironment. When combined with other immunotherapies, macrophage function modulation using CHP nanogels demonstrated a potent inhibitory effect against cancers resistant to immune checkpoint inhibition therapies. In this review, we discuss the applications of our unique drug nanodelivery system for CHP nanogels.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cancer Vaccines / Neoplasms Limits: Humans Language: En Journal: J Control Release Journal subject: FARMACOLOGIA Year: 2022 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cancer Vaccines / Neoplasms Limits: Humans Language: En Journal: J Control Release Journal subject: FARMACOLOGIA Year: 2022 Type: Article